With demand for GLP-1 agonists outstripping supply, Zepbound (tirzepatide) developer Eli Lilly (NYSE: LLY) has issued a warning against resorting to counterfeits.
In a statement, the firm said it was “deeply concerned” that compounding pharmacies or counterfeiters could be offering products which are fraudulently claimed to be Zepbound, an obesity med with impressive and clinically-proven weight loss credentials.
Also marketed as Mounjaro for diabetes, the product is competing with market leader Wegovy (semaglutide), from Novo Nordisk (NOV: N), which has also seen extremely high demand.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze